What Is Wegovy?
Wegovy is an injectable prescription medicine indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who also possess weight-related medical comorbidities such as hypertension, dyslipidaemia, or obstructive sleep apnoea.
The Mechanism of Action The active ingredient is Semaglutide, which functions as a GLP-1 Receptor Agonist. Physiologically, it targets the hypothalamus in the brain, which is the centre responsible for appetite regulation. By binding to these receptors, the medication increases the feeling of satiety or fullness and explicitly reduces hunger signals. This biological assistance allows patients to adhere to a calorie-deficit diet with significantly reduced difficulty.
The Benefit of Wegovy
1. Significant Weight Loss
Wegovy mimics a natural hormone (GLP-1) that targets areas of the brain that regulate appetite and food intake. It significantly reduces intrusive thoughts about eating and increases feelings of fullness.
2. Cardiovascular Protection
Wegovy is the first weight-loss medication specifically approved to help prevent life-threatening cardiovascular events. It has been shown to reduce the risk of heart attack, stroke, or cardiovascular death by 20% in adults with known heart disease who are overweight or obese. It also typically leads to improvements in blood pressure and lower levels of cholesterol, bad cholesterol, LDL and triglycerides.
3. Metabolic & Hormonal Health
It helps the body release insulin more effectively and prevents the liver from making too much sugar, which can prevent or manage Type 2 diabetes. For women with Polycystic Ovary Syndrome (PCOS). Wegovy can help regulate menstrual cycles and improve symptoms related to insulin resistance.
The Difference Between Wegovy and Ozempic
A frequent query at our clinic concerns the difference between Wegovy and Ozempic. Although both medications contain Semaglutide, the clinical indication and dosage differ fundamentally.
| Feature | Ozempic | Wegovy |
| Primary Indication | Type 2 Diabetes Control | Chronic Weight Management |
| Active Ingredient | Semaglutide | Semaglutide |
| Maximum Dosage | 1.0 mg | 2.4 mg |
| NPRA Approval | Diabetes Management | Weight Management |
Table 1: Wegovy vs. Ozempic Comparison
Patient Eligibility Criteria
This is a serious medical intervention rather than a cosmetic quick fix. To qualify for a prescription at Klinik Finesse, you must meet the strict NPRA criteria:
- BMI of 30 kg/m² or higher (Obesity)
- BMI of 27 kg/m² or higher (Overweight) only if accompanied by at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia.
This medication requires a valid prescription and ongoing medical monitoring. If you meet the BMI criteria listed above, please schedule a consultation with Dr Zya at Klinik Finesse. We will review your medical history and determine if this protocol is suitable for your specific health profile.